aTyr Pharma, Inc. Stock Price, News & Analysis

The Phase 1b/2a study of efzofitimod (ATYR1923) in pulmonary sarcoidosis patients showed dose-dependent improvements in vital measures, alongside a successful steroid taper. Patients treated with efzofitimod exhibited a reduction in pro-inflammatory biomarkers, indicating potential therapeutic benefits. The company plans to initiate a pivotal Phase 3 study, EFZO-FIT™, in Q3 2022, marking a significant advancement in treatment for pulmonary sarcoidosis.

aTyr Pharma, Inc. (Nasdaq: LIFE) announced a pivotal Phase 3 study of efzofitimod (ATYR1923) for pulmonary sarcoidosis, set to begin in Q3 2022. The EFZO-FIT™ study aims to enroll 264 patients, comparing two doses of efzofitimod against a placebo over 52 weeks, with a primary focus on steroid reduction. This outcome aligns with FDA feedback on efficacy endpoints, marking a significant milestone for aTyr and the sarcoidosis community. Efzofitimod is designed to modulate immune responses that can lead to improved patient outcomes and reduced steroid-related toxicity.

aTyr Pharma, Inc. (Nasdaq: LIFE) announced the grant of nonstatutory stock options to four employees. A total of 113,400 shares have been offered at an exercise price of $3.48 each, matching the stock's closing price on May 10, 2022. These options are part of aTyr's 2022 Inducement Plan to incentivize new hires. Each option vests over four years, with a portion vesting after one year. aTyr focuses on developing innovative therapies based on its tRNA synthetase biology platform, particularly targeting fibrotic lung diseases with its candidate efzofitimod.

SAN DIEGO, May 10, 2022 – aTyr Pharma (Nasdaq: LIFE) announced its participation in two investor conferences in May.

Details include:

• RBC Capital Markets Global Healthcare Conference: May 18, 2022, at 10:30 a.m. EDT, New York, NY, featuring CEO Sanjay S. Shukla in a fireside chat.
• H.C. Wainwright Global Investment Conference: May 24, 2022, at 4:30 p.m. EDT, Miami, FL, with Ashlee Dunston, Director of Investor Relations, presenting.

Management will also engage in one-on-one investor meetings. Presentations will be available for replay on the company's website.

aTyr Pharma (LIFE) announced key updates during its first quarter 2022 earnings call. The company will present clinical data for efzofitimod in pulmonary sarcoidosis at the ATS International Conference in May and is set to initiate a registrational study in Q3 2022. The FDA granted efzofitimod orphan drug designation for systemic sclerosis, and the company is exploring broadening its clinical program. As of March 31, 2022, aTyr reported cash and investments of $98.7 million, with research and development expenses totaling $8.9 million for the quarter.

aTyr Pharma (Nasdaq: LIFE) will release its Q1 2022 financial results and provide a corporate update on May 9, 2022, after market close. The management team will host a conference call at 5:00 p.m. EDT to discuss the results and future developments. aTyr Pharma focuses on developing innovative biotherapeutics, particularly through its lead candidate, efzofitimod, which targets the neuropilin-2 receptor involved in fibrotic lung disease. For more details, visit aTyr Pharma's website.

aTyr Pharma has received its second orphan drug designation from the FDA for efzofitimod to treat systemic sclerosis (SSc). This designation supports the development of medicines for rare diseases affecting under 200,000 people in the U.S. Efzofitimod is a promising immunomodulator that may also provide treatment options for interstitial lung disease (ILD), driven by similar immune cell activity. The drug has shown efficacy in reducing lung and skin fibrosis in animal studies. SSc affects approximately 100,000 people in the U.S., with a significant percentage developing ILD.

aTyr Pharma (Nasdaq: LIFE) has presented promising findings at the 2022 AACR Annual Meeting regarding their monoclonal antibody, ATYR2810. This agent showed potential in reducing metastasis and improving chemosensitivity in triple-negative breast cancer (TNBC) by downregulating genes linked to these processes. The treatment inhibited spontaneous lung metastasis in preclinical models. aTyr plans to initiate a Phase 1 study later this year, advancing their innovative research in targeting the NRP2/VEGF pathway for treating aggressive cancers.

aTyr Pharma announced promising results from a Phase 1b/2a study of efzofitimod in pulmonary sarcoidosis patients, demonstrating a safety profile and significant dose-dependent efficacy compared to placebo. Key findings include reduced pro-inflammatory biomarkers and improved inflammatory responses in evaluated patients. The company plans to present further clinical data at the ATS 2022 International Conference in May 2022 and aims to initiate a registrational study in Q3 2022, signaling potential advancements in the treatment of fibrotic lung diseases.